<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689376</url>
  </required_header>
  <id_info>
    <org_study_id>16040</org_study_id>
    <nct_id>NCT01689376</nct_id>
  </id_info>
  <brief_title>Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)</brief_title>
  <official_title>Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed
      with metastatic and / or unresectable GIST who have progressed after standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This &quot;Managed Access Program&quot; covers the different types of programs in the participating
      countries (including compassionate use program, named patient program, cohorts e.g. ATU in
      France, etc).
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (BAY73-4506)</intervention_name>
    <description>160 mg BAY73-4506, 3 weeks on drug, 1 week off drug</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed consent (IC) and data protection clarification obtained before any
             specific treatment related procedures. Patients or their legal representative must be
             able to understand and willing to sign a written IC.

          -  Male or female patients &gt;= 18 years of age

          -  Patients with histologically confirmed metastatic and / or unresectable GIST

          -  At least imatinib and sunitinib as prior treatment regimens with progression on or
             intolerance to imatinib and sunitinib

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of =&lt; 1

          -  Adequate bone marrow, liver and renal function

          -  Women of childbearing potential and men must agree to use adequate contraception
             before entering the program until at least 8 weeks after the last regorafenib
             administration in the program. The treating physician or a designated associate is
             requested to advise the patient on how to achieve adequate birth control. Adequate
             contraception is defined in this program as any medically recommend method (or
             combination of methods) as per standard of care.

        Exclusion Criteria:

          -  Prior treatment with regorafenib

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to starting regorafenib

          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
             pregnancy test performed a maximum of 7 days before start of treatment, and a negative
             result must be documented before start of regorafenib.

          -  Congestive heart failure New York Heart Association (NYHA) class 2

          -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3
             months)

          -  Myocardial infarction less than 6 months before start of regorafenib

          -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are
             permitted)

          -  Uncontrolled hypertension. (Systolic blood pressure &gt; 140 mmHg or diastolic pressure &gt;
             90 mmHg despite optimal medical management)

          -  Pleural effusion or ascites that causes respiratory compromise (National Cancer
             Institute's common terminology criteria for adverse events [NCI-CTCAE] v.4.0 Grade &gt;=
             2 dyspnea)

          -  Ongoing infection NCI-CTCAE v.4.0 Grade &gt; 2

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with
             antiviral therapy

          -  Patients with seizure disorder requiring medication

          -  History of organ allograft

          -  Patients with evidence or history of any bleeding diathesis, irrespective of severity

          -  Any hemorrhage or bleeding event NCI-CTCAE v. 4.0 Grade &gt;= 3 within 4 weeks prior to
             the start of regorafenib

          -  Non-healing wound, ulcer, or bone fracture

          -  Renal failure requiring hemo- or peritoneal dialysis

          -  Dehydration NCI-CTCAE v.4.0 Grade &gt;= 1

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the program

          -  Known hypersensitivity to regorafenib, the drug class, or excipients in the
             formulation

          -  Any illness or medical conditions that are unstable or could jeopardize the safety of
             the patient and his / her compliance in the program

          -  Interstitial lung disease with ongoing signs and symptoms

          -  Persistent proteinuria of NCI-CTCAE v.4.0 Grade 3 (&gt; 3.5 g/24 hours)

          -  Patients unable to swallow oral medications

          -  Any malabsorption condition

          -  Unresolved toxicity higher than NCI-CTCAE v.4.0 Grade 1 (excluding alopecia, anaemia,
             and hypothyroidism) attributed to any prior therapy / procedure

          -  Concomitant participation or participation within the last 30 days in a clinical trial

          -  Non-permissible concomitant medications and procedures (systemic anti-cancer therapy
             including cytotoxic therapy, signal transduction inhibitors, immunotherapy and
             hormonal therapy or any experimental therapies; Tyrosine Kinase Inhibitors (TKIs);
             bone marrow transplant or stem cell rescue; use of biologic response modifiers, such
             as granulocyte colony stimulating factor (G CSF), within 3 weeks prior to entering the
             program; St John's Wort; grapefruit and grapefruit juice; all traditional medicines
             with an anti-cancer indication)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>September 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

